Form 4: OmniAb Director Carolyn Bertozzi Reports Significant Equity Transactions, Including RSU Vesting and New Grants

OmniAb, Inc. Director Carolyn R. Bertozzi has reported the vesting of 20,000 Restricted Stock Units (RSUs) into common stock, alongside the acquisition of 20,000 new RSUs and 40,000 stock options, aligning her interests with the company's future performance.

Summary

• Carolyn R. Bertozzi, a Director at OmniAb, Inc. (OABI), filed a Form 4 detailing changes in her beneficial ownership.
• On June 17, 2025, 20,000 Restricted Stock Units (RSUs) granted on June 18, 2024, vested and converted into 20,000 shares of OmniAb Common Stock.
• Following this vesting, Ms. Bertozzi's direct beneficial ownership of Common Stock increased to 75,539 shares.
• Concurrently, Ms. Bertozzi was granted an additional 20,000 Restricted Stock Units (RSUs) on June 17, 2025, which will vest on the earlier of the next annual meeting or the first anniversary of the grant date.
• She also received a grant of 40,000 Stock Options on June 17, 2025, with an exercise price of $1.7 per share, which will vest and become exercisable on the earlier of the next annual meeting or the first anniversary of the grant date, and expire on June 17, 2035.
• After these transactions, Ms. Bertozzi holds 37,769 RSUs and 40,000 Stock Options directly.

Sentiment

Score: 7

Explanation: The document reports routine equity compensation for a director, including vesting and new grants. This is generally positive as it aligns the director's interests with shareholders and indicates continued commitment, without any negative implications like share sales.

Positives

• The vesting of 20,000 RSUs into common stock increases Director Carolyn Bertozzi's direct ownership, signaling continued commitment and alignment with shareholder interests.
• The grant of an additional 20,000 RSUs and 40,000 stock options to a director indicates ongoing equity-based compensation, which is a common practice to incentivize long-term performance and retention of key personnel.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged, compliant approach to insider trading.

Risks

• The value of the newly acquired common stock, RSUs, and stock options is subject to the future performance and stock price fluctuations of OmniAb, Inc.

Future Outlook

The document indicates future vesting events for the newly granted Restricted Stock Units and Stock Options, which are tied to the earlier of the next annual meeting of stockholders or the first anniversary of the grant date (June 17, 2025). The stock options have an expiration date of June 17, 2035.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in publicly traded companies, particularly in the biotechnology or pharmaceutical sectors where long-term incentives are common to align leadership with company growth and innovation.

Comparison to Industry Standards

• Equity compensation, including Restricted Stock Units (RSUs) and stock options, is a prevalent practice for compensating non-employee directors across various industries, including biotechnology and healthcare, to align their interests with long-term shareholder value.
• The vesting schedules tied to annual meetings or anniversaries are typical for director equity grants, similar to practices observed at companies like Regeneron Pharmaceuticals (REGN) or Amgen (AMGN) for their board members.
• The exercise price of $1.7 for the stock options would be compared against OmniAb's stock price on the grant date to assess if they were granted at-the-money or in-the-money, a common consideration in compensation analysis.

Stakeholder Impact

• Shareholders: The increase in director's beneficial ownership and new equity grants align the director's financial interests with the long-term performance of OmniAb, potentially fostering better governance and strategic decisions aimed at increasing shareholder value.

Next Steps

• Future vesting of the 20,000 new RSUs on the earlier of the next annual meeting or June 17, 2026.
• Future vesting and exercisability of the 40,000 stock options on the earlier of the next annual meeting or June 17, 2026.

Key Dates

Recommendation

Keywords

OmniAb, OABI, SEC Form 4, Insider Trading, Director Compensation, Restricted Stock Units, Stock Options, Equity Compensation, Beneficial Ownership, Carolyn R Bertozzi